Weight & metabolism
MOTS-c
Mitochondrial-derived peptide
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA that researchers study as a signal involved in metabolism. It is not an approved drug, and its effects as a treatment have not been tested in published human trials.
Key facts
- Commonly discussed for: metabolic health, insulin sensitivity and exercise capacity.
- Evidence (D): The foundational 2015 Cell Metabolism study was in mice, and a 2023 review notes no effective clinical method for using MOTS-c has been developed. Human studies so far measure natural blood levels rather than test it as a treatment.
- FDA status: PCAC recommended. On July 23, 2026 the PCAC voted 7-5 (2 abstentions) to recommend MOTS-c for the 503A Bulks List for obesity and osteoporosis. In a notice published Oct 30, 2026, HHS said it does not intend to take enforcement action against licensed pharmacies and physicians compounding it under set conditions while the FDA writes rules. That is interim enforcement discretion, not FDA approval, and the FDA had not proposed adding it to the list as of Nov 18, 2026.
- Legitimate access: Prescription compounding under an interim HHS policy (not FDA-approved).
- Last reviewed: October 1, 2026.
Read the deep dives
Common questions
Is MOTS-c FDA approved?
No. MOTS-c is not an FDA-approved drug and has not been tested as a treatment in published human trials.
What did the PCAC vote mean for MOTS-c?
On July 23, 2026 the Pharmacy Compounding Advisory Committee voted 7-5 (2 abstentions) to recommend adding MOTS-c to the 503A Bulks List. A vote is advice, not approval: FDA still has to publish a proposed rule, and none had appeared as of November 18, 2026.
Sources
- Lee et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab, 2015
- Zheng et al. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Front Endocrinol, 2023
- McDermott Will & Schulte: PCAC backs majority of peptides in two-day public meeting (July 2026)
- Federal Register notice of PCAC meeting and uses under review (April 16, 2026)